DHG Pharmaceutical JSC (HOSE:DHG)
Vietnam · Delayed Price · Currency is VND 100,400
+100 (0.10%)
At close: Apr 10, 2026
DHG Pharmaceutical JSC Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5,266,963 | 4,884,868 | 5,015,395 | 4,676,016 | 4,003,170 | |
Revenue Growth (YoY) | 7.82% | -2.60% | 7.26% | 16.81% | 6.59% |
Cost of Revenue | 2,760,594 | 2,747,102 | 2,671,850 | 2,418,521 | 2,082,260 |
Gross Profit | 2,506,369 | 2,137,766 | 2,343,545 | 2,257,495 | 1,920,911 |
Selling, General & Admin | 1,553,700 | 1,217,491 | 1,291,264 | 1,181,417 | 1,060,127 |
Operating Expenses | 1,553,700 | 1,217,491 | 1,291,264 | 1,181,417 | 1,060,127 |
Operating Income | 952,669 | 920,276 | 1,052,281 | 1,076,078 | 860,784 |
Interest Expense | -25,635 | -24,811 | -29,530 | -12,559 | -12,080 |
Interest & Investment Income | 123,012 | 138,160 | 202,173 | 120,337 | 114,306 |
Currency Exchange Gain (Loss) | -578.16 | -2,514 | 5,580 | 3,587 | 4,160 |
Other Non Operating Income (Expenses) | -60,631 | -127,857 | -73,082 | -89,517 | -93,955 |
EBT Excluding Unusual Items | 988,837 | 903,254 | 1,157,423 | 1,097,926 | 873,214 |
Gain (Loss) on Sale of Investments | 192.5 | 262.5 | 315 | -772.55 | 274.7 |
Gain (Loss) on Sale of Assets | -2,430 | 967.73 | 1,437 | 2,518 | -7,999 |
Other Unusual Items | - | - | - | -58.33 | -1,488 |
Pretax Income | 986,599 | 904,485 | 1,159,174 | 1,099,613 | 864,002 |
Income Tax Expense | 134,245 | 125,564 | 108,512 | 111,159 | 87,717 |
Earnings From Continuing Operations | 852,354 | 778,920 | 1,050,663 | 988,455 | 776,285 |
Minority Interest in Earnings | - | - | - | - | 934.93 |
Net Income | 852,354 | 778,920 | 1,050,663 | 988,455 | 777,220 |
Preferred Dividends & Other Adjustments | 27,571 | 25,368 | 33,520 | 31,654 | 29,317 |
Net Income to Common | 824,783 | 753,553 | 1,017,143 | 956,801 | 747,903 |
Net Income Growth | 9.43% | -25.86% | 6.29% | 27.18% | 5.05% |
Shares Outstanding (Basic) | 131 | 131 | 131 | 131 | 131 |
Shares Outstanding (Diluted) | 131 | 131 | 131 | 131 | 131 |
EPS (Basic) | 6308.29 | 5763.48 | 7779.53 | 7318.01 | 5720.27 |
EPS (Diluted) | 6308.29 | 5763.48 | 7779.53 | 7318.01 | 5720.27 |
EPS Growth | 9.45% | -25.91% | 6.31% | 27.93% | 5.09% |
Free Cash Flow | 1,181,831 | 1,228,879 | -246,171 | 667,293 | 427,882 |
Free Cash Flow Per Share | 9039.13 | 9398.97 | -1882.82 | 5103.73 | 3272.62 |
Dividend Per Share | - | 10000.000 | 7500.000 | 3500.000 | 3500.000 |
Dividend Growth | - | 33.33% | 114.29% | - | -12.50% |
Gross Margin | 47.59% | 43.76% | 46.73% | 48.28% | 47.98% |
Operating Margin | 18.09% | 18.84% | 20.98% | 23.01% | 21.50% |
Profit Margin | 15.66% | 15.43% | 20.28% | 20.46% | 18.68% |
Free Cash Flow Margin | 22.44% | 25.16% | -4.91% | 14.27% | 10.69% |
EBITDA | 1,070,698 | 1,089,971 | 1,140,985 | 1,157,079 | 943,348 |
EBITDA Margin | 20.33% | 22.31% | 22.75% | 24.75% | 23.57% |
D&A For EBITDA | 118,029 | 169,695 | 88,704 | 81,001 | 82,564 |
EBIT | 952,669 | 920,276 | 1,052,281 | 1,076,078 | 860,784 |
EBIT Margin | 18.09% | 18.84% | 20.98% | 23.01% | 21.50% |
Effective Tax Rate | 13.61% | 13.88% | 9.36% | 10.11% | 10.15% |
Revenue as Reported | 5,266,963 | 4,884,868 | 5,015,395 | 4,676,016 | 4,003,170 |
Advertising Expenses | 166,410 | 61,742 | 128,162 | 138,011 | 138,095 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.